Look Back Icon

Biomarkers & Precision Medicine 2025

Thank you for attending

From beginning to end, Biomarkers & Precision Medicine 2025 showcased the remarkable innovation within our community. 

An incredible two days of learning, networking, and innovation. We've seen how the latest breakthroughs in multi-omics, AI, and digital pathology are not just abstract concepts, but the building blocks of a new era in precision medicine.

A huge thank you to all our speakers for sharing their expertise and to every attendee for their active participation. The future of biomarkers and precision medicine is bright, and it's because of this brilliant community.

BIOMUK - Look Back Page Top Section Image

Lights, Camera, Action!

Explore our curated photo gallery of standout moments from Biomarkers & Precision Medicine 2025. See if you can spot yourself!

Precision Medicine Awards 2025

WINNERS

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

AI Innovation of the Year

Nexomic

Biomarkers & Precision Medicine On-Demand

Relive all of the fantastic content from our industry leading Biomarkers & Precision Medicine events. 

We've turned select sessions into a 5-minute quick watch video, pulling all the key insights together so you can understand trends, benchmark your work, inform your strategy and get to market, faster! 
 
Get all of the key insights in one place by accessing LifeScienceXchange now.

NGB x LSX Laptop Image-3
Precision Medicine Awards 2025 Logo (Light)

Join us at the Precision Medicine Awards 2025, for an evening dedicated to celebrating visionary institutions and individuals who are driving innovation & excellence in Precision Medicine. Held at the stunning Grade II listed Assembly Hall at Church House - just a 3 minute walk from the conference venue - this prestigious event offers a unique timely opportunity to celebrate and honour groundbreaking achievements in the industry which are accelerating targeted treatments and transforming patient outcomes. 

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Biomarkers & Precision Medicine 2025: 30 September - 01 October 2025, London, UK

Elena Miranda
Director of Non Clinical Histology,
GSK
Espen Walker
Global Head of Medical Diagnostics,
AstraZeneca
Jeroen van der Laak
Professor of Computational Pathology,
Radboudumc
Maria Orr
Head of Precision Medicine and Biosamples and Early Oncology,
AstraZeneca
Mark Caufield
Professor and Vice Principal for Health, Queen Mary’s Faculty of Medicine and Dentistry; Director of the NIHR Barts Biomedical Research Centre; President of British Pharmacological Society,
Queen Mary University of London
Matt Brown
Chief Scientific Officer,
Genomics England
Paul Van Diest
Professor and Head, Department of Pathology ,
UMC Urtecht
Stephanie Craig
Lecturer in Precision Medicine,
Queen's University Belfast
Svetlana Mukhina
Director Global Regulatory Affairs, CDx,
Merck Group
Virginia Savova
Senior Director, Cell-Targeted Precision Medicine,
AstraZeneca
Adama Ibrahim
Vice President Digital Transformation,
Novo Nordisk
Alain Van Gool
Professor Personalised Healthcare,
Radboud University Medical Center
Alex Dulovic
Group Leader,
NMI Natural and Medical Sciences Institute at the University of Tübingen
Alexandra Sevko
VP of Translational Science,
Amphista Therapeutics
Amonida Zadissa
Associate Director,
UK Dementia Research Institute
Arman Rahman
Assistant Professor of Anatomy,
University College Dublin
Arthur Lewis
Director of Image Analysis & Platform, Pathology,
AstraZeneca
Azam Hamidinekoo
Associate Director, Clinical Pharmacology & Safety Sciences,,
AstraZeneca
Belinda Nedjai
Associate Professor in Cancer Biomarker and Epigenetics & Director, Molecular Epidemiology Laboratory,
Queen Mary University Of London
Bernd Wollscheid
Professor,
ETH Zürich
Chris Bray
Head of Global Regulatory Affairs, Precision Medicine & Companion Diagnostics,
Merck & Cie KmG
Cristina Legido-Quigley
Group leader Systems Medicine,
King's College London
d Snead
cmo,
h
Danny Kaye
Lead Digital Pathology Scientist,
Leeds Teaching Hospitals NHS Trust, NPIC
David Clark
Consultant Haematopathologist,
Nottingham University Hospitals NHS Trust
David Krige
Head of Translational Sciences,
Accession Therapeutics
Deepak Bhere
Assistant Professor and Principal Investigator,
University of South Carolina School of Medicine
Edina Silajdzic
Lecturer,
King's College London
Emanuela Oldoni
Scientific Lead of Personalised Medicine,
EATRIS
Emily Adams
Associate Professor,
University of Oxford
Emmanuel Valentin
Vice President of Translational Medicine,
Imcheck Therapeutics
Folake Orafidiya
Senior Scientist,
Avacta Therapeutics
Francesca Trapani
Scientific Director and Molecular Pathology Laboratory Head,
Boehringer Ingelheim
Gayle Marshall
Head of Biomarkers,
Catapult Medicines Discovery
Giovanna Lalli
Director of Strategy & Operations,
LifeArc
Harpreet Saini
Senior Director of Bioinformatics,
Astex Pharmaceuticals
Helen Graves
Principal Scientist,
Alchemab Therapeutics
Henoch Hong
Associate Director,
Merck Healthcare KGaA
Huw Bannister
Senior Director of Global Diagnostics, Digital and Computational Pathology,
AstraZeneca
Inês Sequeira
Associate Professor, Group Leader, Spatial Biology Hub Lead,
Queen Mary University of London
Irene Del Molino del Barrio
Principal Scientist,
GSK
James Schofield
Founder & Chief Executive Officer,
TopMD
Jan-Philipp Mallm
Head of Single Cell Open Lab,
DKFZ
Jean-Baptiste Lugagne
Group Leader & Assistant Professor,
Centre for Medicines Discovery
Jean-Christophe Olivo-Marin
Professor & Head of the Quantitative Image Analysis Unit,
Institute Pasteur
Jens Kieckbusch
Director of External Innovation, Precision Medicine, Research & Development,
GSK
Jim Eyles
Director of Clinical Immuno-Oncology Discovery Group,
AstraZeneca
Jimmy Bell
Professor & Director, Research Centre for Optimal Health,
University of Westminster
Jo Taylor
Founder,
METUPUK
Joanna Janus
Research Programme Manager (Early Detection and Prevention),
Cancer Research UK
Joao Pinto
Medical Specialist, Institute of Molecular Pathology and Immunology, University of Porto (Ipatimup) ,
Institute of Molecular Pathology and Immunology, University of Porto (Ipatimup)
Johan Luthman
Executive Vice President and Head of R&D,
Lundbeck
Jose Izarzugaza
Director of Biomarker and MoA Insights,
Novo Nordisk
Joshua Atkins
Senior Genomic Epidemiologist,
Cancer Epidemiology Unit (CEU) - University of Oxford
Karin Schmitt
Chief Operating Officer,
Mursla Bio
Karl Smith-Byrne
Senior Molecular Epidemiologist, Cancer Epidemiology Unit (CEU),
Centre for Medicines Discovery, University of Oxford
Kazumasa Kanemaru
Postdoctoral Researcher,
Teichmann Group, Cambridge Stem Cell Institute, University of Cambridge
Kiri Granger
Chief Scientific Officer,
Monument Therapeutics
Kristina Holmberg
Head of Clinical Biomarkers,,
Lundbeck
Laurent Audoly
Co-Founder,
PriveBio
Liz Harrington
Global Head of Translational Medicine, Targeted Therapy Franchise,
Astrazeneca
Mani Mudaliar
Director of Quantitative Biomarkers,
Recursion
Manuel Salto-Tellez
Professor of Integrative Pathology and Director of Integrated Pathology Unit,
The Institute of Cancer Research
Manuela Cerina
Scientific Director of Neurodegeneration,
LifeArc
Maria Laura Garcia Bermejo
Scientific Director & Co-Chair,
Ramon y Cajal Health Research Institute (IRYCIS)
Marisca Marian
Oncology Market Access Strategy Leader,
Bayer AG
Markus Schulze
Senior Scientist, Clinical Biomarkers and Technologies,,
Merck & Cie KmG
Matthew Humphries
Director of Research Operations,
NHS
Michael Cannarile
Head of Oncology Biomarkers,
Roche
Miguel Souto
Director of Business Development & Innovation,
Idibell
Mike Messenger
Head of Regulatory Strategy,
BIVDA
Miro Venturi
Operating Partner,
ARCHIMED
Muhammad Aslam
Consultant Pathologist, National Clinical Lead for Digital Pathology and AI, Wales,
Betsi Cadwaladr University Health Board
Nathalie Banner
Director of Ethics,
Genomics England
Neil Humphryes-Kirilov
Associate Director of Human Genomics,
C4X Discovery
Nik Matthews
Head of the Imperial BRC Genomics Facility,
Faculty of Medicine, Imperial College London
Nitin Jain
Director, Franchise Project Management,
AstraZeneca
Olga Nissan
Chief Executive Officer,
Protica Bio
Peter Groenen
Head of Translational Science, Owner & Consultant,
Cerebrum DAO
Priya Narayanan
Senior Scientific Officer,
Mogrify
Rahul Deb
Consultant Histopathologist, Lead Breast Pathologist,
University Hospitals of Derby and Burton NHS Foundation
Richard Festenstein
Clinical Professor of Molecular Medicine, Department of Brain Sciences,
Imperial College London
Richard Barker
Founder,
Nmp
Sonali Natu
Consultant Cellular Pathologist, Tees Valley Pathology Services and Clinical Lead for Pathology,
Incisive Health
Stephanie Traub
Associate Director,
UCB
Thomas Jensen
Chief Executive Officer,
Allarity Therapeutics
Thomas Hach
Global Program Clinical Head,
Novartis
Valerie Taly
President/CSO,
METHYS Dx
Victoria Goss
Head of Early Diagnosis and Translational Group,
University of Southampton
Victoria Goss
Head of Early Diagnosis and Translational Group,
University of Southampton
Vihanga Pahalawatta
Director of Regulatory Affairs Companion Diagnostics,
AbbVie
Wanderson Dos Santos Trindade
Director of Global Regulatory Affairs, & Companion Diagnostics,
Daiichi Sankyo
Wolfgang Breitwieser
Head of Molecular Biology,
Cancer Research -UK Manchester Institute
Wouter De Jonge
Professor of Neurogastroenterology,
Amsterdam UMC

The Start-up Zone

Are you developing a cutting-edge therapy, platform or technology? Our Start-Up Zone is designed to support emerging companies looking to increase their visibility, find potential partners or early adopters, and meet their investment goals – connecting them with our community of pharma, investors, and mid-to-large size biotechs. 

Located in the Exhibition Hall, the Start-Up Zone allows therapeutic pioneers to showcase their approach, conduct invaluable 1:1 meetings and deliver a quick-fire pitch.

To get involved, apply today and our Start-Up Lead will be in touch to discuss further.

Criteria:

The Start-Up Zone is designed for therapeutic start-ups, academic spin-outs, and early-stage technology/service providers.

To be eligible for inclusion, you must meet the following criteria:

•    0 – 5 years operating
•    0 – 30 employees
•    Pre-Series A funding

Successful applicants will receive as part of their package:

•    2 full conference passes
•    10-minute pitch on the Start-Up Stage
•    1x1m space in Start-Up Zone: cocktail table provided, start-up to bring 1x pull-up banner
•    Logo featured on website & event platform as a participating start-up
•    Ability to arrange 1:1 meetings via to the congress app

What's been happening at NextGen Omics & Spatial Biology US 2025?

Have a peek into the dynamic panels, engaging roundtables, and hands-on workshops happening in Boston - right now!

spatial biology Track keynote address 
 Spatial Multi-Omics For Target-To-Disease Linkage In Inflammatory Diseases

MARINA BLECK, Principal Scientist, Boehringer Ingelheim

Marina discussed the use of multi omics for faster Faster Target-to- Disease Link (T2DL) with increased confidence and how they can leverage Spatial Biology to enhance the ability to derive insight from human disease tissues.  Finally the Importance of FFPE Tissue Quality for Spatial Biology was discussed with the use of QC scoring to determine which FFPE tissue gives the best spatial transcriptomics results.

spatial biology day one, track 6 
Spatial Biology As A Discovery Pathway

EMRE ARSLAN, Takeda

Emre Arslan from Takeda gave a talk about the use of Spatial Biology as a discovery pathway. First of all providing an update on the current landscape for spatial technologies then analysing how spatial technologies can be used in clinical trial design - such as the ability to identify previously unknown cell types, interactions and microenvironments and providing an ideal foundation for training better AI models. 

day 2 keynote
Single Cell into Spatial and Beyond: Landscape in 2025 and What’s Next?

JASMINE PLUMMER, Director, St Jude Children's Research Hosptial

Jasmine Plummer's day 2 keynote focused on Single cell into spatial and beyond.  "The reason we are in this room is because it’s cutting edge" which is why the single cell and spatial field growing exponentially.

Future directions for the technology include Low throughput, clinical trials, other organisms, more tissue types, epigenomics

Spatial multi-omics, track 4 Keynote
Rapid Single-Cell Spatial Proteomics by Spatial MIST

JUN WANG, Associate Professor, Multiplex Biotechnology Laboratory, Department of Biomedical Engineering, Stony Brook University

"Simpler but more powerful than flow and imaging cytometry"

MIST Technology provides100 times more information than flow cytometry and currently the highest multiplexity is up to 500 markers/ cell.

Single cell track keynote address
Panel Application Of Single Cell Omics In Clinical Monitoring

PRIYA CHOCKALINGAM, Vice President, Head of Clinical BioAnalytics & Translational Sciences, Beam Therapeutics

Priya's talk focused on Genome Editing Technologies for Gene & Cell Therapy and how cell & gene therapies require a specialized regulatory approach compared to other modalities. Appropriate assessments should therefore be put in place in both nonclinical and clinical stages to address safety concerns.

Various methods to assess off-target editing effects have evolved in the last decade. However, limitations remain in balancing accuracy vs sensitivity of these new techniques.

The direct assessment of off-target effects in vivo and in patients is particularly challenging.

Novel single-cell technologies enable quantitation/co-occurrence of on-/off-target editing through patient time-course of treatment

single cell  
Comparative Insights In Single Cell RNA-seq & Advances In Large-Scale Multimodal Profiling

ZORA MODRUSAN, Senior Director NGS, Genentech

Zora focused on both key insights and future directions of single cell RNA-Seq.  scRNA-seq technologies were evaluated and the differences in performance across various metrics such as sensitivity, throughput and cost were compared across different systems.

The Overloading And unpacKing (OAK) method provides a reliable solution for large-scale molecular profiling that incorporates multiple data modalities.

Moving forward they will continue to evaluate the latest scRNA-seq kits to understand differences and guide optimal performance. Zora would also like to enhance OAK's capabilities by integrating additional modalities and applying the platform to a wide range of biological systems.

Training Partner

Succession - Powering Go-To-Market For Life Science Teams

Powering Go-To-Market For Life Science Teams

Succession helps founders and sales teams close more deals with biotech and pharma. We partner with our clients to run modern lead generation campaigns, up-skill their team through personalized sales training, and build AI workflows using cutting edge tools and technology.

Close more deals with biotech and pharma

Interested in Sponsoring Biomarkers & Precision Medicine 2026?

Become a driving force in accelerating the next generation of personalized treatments. Biomarkers & Precision Medicine 2025 offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, & academic experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, & collaborate with the community shaping the future of precision medicine today.

Interested in Biomarkers, CDx & Precision Medicine 2026?